|Articles|January 1, 1998

A Managed Care Appraisal of Atypical Agents in the Treatment of Psychoses
Volume 4
Issue 1 Suppl

Chronic Ambulatory Outpatients and Four-Vector Management

Author(s)Richard Petty, MD

Download PDF: Chronic Ambulatory Outpatients and Four-Vector Management

Articles in this issue

over 28 years ago

Article

Common Treatment Goals: Switching Antipsychotics

over 28 years ago

Article

Antipsychotics : Present and Future

over 28 years ago

Article

Atypical Antipsychotics in the Managed Care Era

over 28 years ago

Article

CME Quiz

over 28 years ago

Article

Selected Abstracts

over 28 years ago

Article

Bibliography

over 28 years ago

Article

Participating Faculty

over 28 years ago

Article

Introduction - The Routine Use of Atypical Antipsychotics

over 28 years ago

Article

Atypical Antipsychotics and Formulary Decisions

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Chronic Ambulatory Outpatients and Four-Vector Management

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

FDA Advisory Panel Weighs Access to 7 Popular Peptides This Week

Trump Announces Timeline for 100% Generic Drug Tariffs Beginning in 2028, 200% in 2029

Eplontersen Misses Primary End Point in Phase 3 ATTR-CM Cardiovascular Outcomes Trial

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Dermatology Practices Absorb Rising Prior Authorization Costs